Cardiac amyloidosis is a systemic disease characterized by the extracellular deposition of amyloid proteins in the cardiac tissue. This activity will include case studies, updates, and a patient’s perspective on the pathophysiology, diagnosis, current, and emerging therapeutic options, and guideline-directed management of immunoglobulin light chain cardiac amyloidosis and transthyretin amyloidosis.
The goal of this activity is to improve the heart failure clinician’s knowledge of the
diagnosis, evaluation, and treatment selection.
This educational activity is intended for Physicians, Nurses, Nurse Practitioners, Pharmacists, Scientists, and Health Care Professionals who specialize or have an interest in heart failure.
This activity is supported by unrestricted Educational Partner Accredited Sponsor educational grants provided by the Amyloidosis Research Consortium, Eidos Therapeutics, Ionis Pharmaceuticals, and Pfizer.
Original recording Date: September 11, 2021